tradingkey.logo
tradingkey.logo
検索

Alkermes Plc

ALKS
ウォッチリストに追加
55.080USD
0.0000.00%
終値 06/26, 16:00ET15分遅れの株価
9.09B時価総額
59.24直近12ヶ月PER

詳細情報 Alkermes Plc 企業名

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Alkermes Plcの企業情報

企業コードALKS
会社名Alkermes Plc
上場日Jul 16, 1991
最高経営責任者「CEO」Pops (Richard F)
従業員数1800
証券種類Ordinary Share
決算期末Jul 16
本社所在地Connaught House
都市DUBLIN
証券取引所NASDAQ OMX - NASDAQ BASIC
Ireland
郵便番号D04 C5Y6
電話番号35317728000
ウェブサイトhttps://www.alkermes.com/
企業コードALKS
上場日Jul 16, 1991
最高経営責任者「CEO」Pops (Richard F)

Alkermes Plcの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
229.52K
-0.89%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
77.39K
-5.17%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
35.75K
+13.05%
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
33.77K
+13.82%
Dr. Christopher I. Wright, M.D., Ph.D.
Dr. Christopher I. Wright, M.D., Ph.D.
Independent Director
Independent Director
25.68K
-7.79%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Independent Director
Independent Director
18.22K
+25.61%
Dr. Nancy L. Snyderman, M.D.
Dr. Nancy L. Snyderman, M.D.
Independent Director
Independent Director
--
--
Mr. C. Todd Nichols
Mr. C. Todd Nichols
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
229.52K
-0.89%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
77.39K
-5.17%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
35.75K
+13.05%
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
33.77K
+13.82%

よくある質問

Alkermes Plcの上位5名の株主は誰ですか?

Alkermes Plcの上位5名の株主は以下のとおりです。Mr. Richard F. Pops

Alkermes Plc(ALKS)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Alkermes Plcの株式を保有している機関は783社あり、保有株式の総市場価値は約182.39Mで、全体の109.43%を占めています。2025Q4と比較して、機関の持ち株は-11997400.00増加しています。

Alkermes Plcの最大の収益源は何ですか?

2026Q1において、VIVITROL部門がAlkermes Plcにとって最大の収益を生み出しており、その金額は467.91Mで、全収益の31.70%を占めています。
KeyAI